Short Interest in ENDRA Life Sciences Inc. (NASDAQ:NDRA) Decreases By 39.2%

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the recipient of a significant decline in short interest in the month of May. As of May 29th, there was short interest totaling 19,820 shares, a decline of 39.2% from the May 14th total of 32,603 shares. Based on an average trading volume of 18,084 shares, the short-interest ratio is presently 1.1 days. Currently, 1.7% of the shares of the company are sold short.

ENDRA Life Sciences Stock Performance

NASDAQ NDRA traded down $0.16 during trading on Tuesday, hitting $4.69. 24,023 shares of the company’s stock traded hands, compared to its average volume of 15,732. The stock has a market capitalization of $5.96 million, a price-to-earnings ratio of -0.58 and a beta of -0.04. ENDRA Life Sciences has a 12-month low of $2.96 and a 12-month high of $11.96. The business has a 50 day moving average of $5.11 and a 200-day moving average of $4.64.

ENDRA Life Sciences (NASDAQ:NDRA) last announced its quarterly earnings data on Friday, May 15th. The company reported ($1.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.14. On average, analysts expect that ENDRA Life Sciences will post -4.11 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Ascendiant Capital Markets lowered their price target on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, ENDRA Life Sciences currently has an average rating of “Hold” and an average target price of $25.00.

Institutional Trading of ENDRA Life Sciences

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new position in ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences makes up 0.9% of Altium Capital Management LLC’s portfolio, making the stock its 17th largest position. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences as of its most recent SEC filing. Hedge funds and other institutional investors own 1.19% of the company’s stock.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.